Patents Examined by Aurora M Fontainhas
-
Patent number: 11958903Abstract: The present application provides anti-LAG-3 constructs comprising a single-domain antibody (sdAb) that specifically recognizes LAG-3. Also provided are methods of making and using these constructs.Type: GrantFiled: March 29, 2019Date of Patent: April 16, 2024Assignee: Nanjing Legend Biotech Co., Ltd.Inventors: Wang Zhang, Shuai Yang, Shu Wu, Chuan-Chu Chou
-
Patent number: 11952416Abstract: Anti-annexin A1 antibodies are provided and methods of treating FAP and cancer using Anti-annexin A1 antibodies, antibody fragments or fusion proteins, including bispecific antibodies targeting two different annexin A1 epitopes, are also provided.Type: GrantFiled: September 14, 2023Date of Patent: April 9, 2024Assignee: The Trustees of Columbia University in the City of New YorkInventor: Yiping Han
-
Patent number: 11946045Abstract: The present invention relates to variant polypeptides, methods of preparing the variant polypeptides, processes for characterizing the variant polypeptides, compositions and cells comprising the variant polypeptides, and methods of using the variant polypeptides. The invention further relates to complexes comprising the variant polypeptides, methods of producing the complexes, processes for characterizing the complexes, cells comprising the complexes, and methods of using the complexes.Type: GrantFiled: December 30, 2022Date of Patent: April 2, 2024Assignee: Arbor Biotechnologies, Inc.Inventors: Shaorong Chong, Wei-Cheng Lu, Brendan Jay Hilbert, Quinton Norman Wessells, Lauren E. Alfonse, Anthony James Garrity
-
Patent number: 11939382Abstract: The disclosure relates to binding proteins, including antibodies, that bind to Programmed Death-1 (“PD-1”) and T cell immunoreceptor with Ig and ITIM domains (“TIGIT”). The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating a disorder or condition using such binding proteins.Type: GrantFiled: April 29, 2022Date of Patent: March 26, 2024Assignee: MedImmune, LLCInventors: Yariv Mazor, Yue Wang, Gordon Moody, Deepali Malhotra, Michael Overstreet, Eleanor Clancy-Thompson, Karin Lee, Stacy Pryts, Scott Hammond
-
Patent number: 11939383Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4. The anti-B7-H4 antibodies or antigen-binding fragments thereof are useful, for example in detecting B7-H4. Immunohistochemistry (IHC) can be used to detect B7-H4. The present disclosure also provides methods for treating cancer wherein increased B7-H4 has been detected, by administering a therapeutic anti-B7-H4 antibody or antigen-binding fragment thereof.Type: GrantFiled: August 28, 2020Date of Patent: March 26, 2024Assignee: FIVE PRIME THERAPEUTICS, INC.Inventors: Charles Kaplan, Alessandro Palumbo, Kathy Miller, Hangil Park, Nerissa Mendoza, Majid Ghoddusi
-
Patent number: 11932702Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from cancer. Specifically, the technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that one ISVD binds to TCR and at least two ISVDs bind to GPC3. The present technology also provides nucleic acids, vectors and compositions.Type: GrantFiled: December 17, 2021Date of Patent: March 19, 2024Assignees: Ablynx N.V., SanofiInventors: Daniel Janssen, Carlo Boutton, Evelyne Dombrecht, Bram Laukens, Paolo Meoni, Lily Pao, Jan Pype, Peter Schotte, Benedikte Serruys, Ana Paula Vintem, Diane Van Hoorick
-
Patent number: 11926659Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.Type: GrantFiled: February 22, 2021Date of Patent: March 12, 2024Assignee: Prothena Biosciences LimitedInventors: Tarlochan S. Nijjar, Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
-
Patent number: 11925678Abstract: Methods for diagnosing and treating Alzheimer's disease are provided. In particular, methods of restoring blood-brain barrier integrity and/or promoting vascular reversion in a person suffering from Alzheimer's disease by administering an anti-angiogenic agent or an agent that is capable of restoring tight junction integrity. Methods of preventing or delaying the onset of Alzheimer's disease in a subject are also provided.Type: GrantFiled: September 18, 2020Date of Patent: March 12, 2024Assignee: Cava Healthcare Inc.Inventors: Wilfred Jefferies, Kaan E. Biron, Dara L. Dickstein
-
Patent number: 11926660Abstract: The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of Aß plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.Type: GrantFiled: August 24, 2021Date of Patent: March 12, 2024Assignee: Washington UniversityInventors: David Holtzman, Hong Jiang, Thu Nga Bien-Ly, Mark S. Dennis, Jing Guo, Adam P. Silverman, Ryan J. Watts, Yin Zhang
-
Patent number: 11926661Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind to human artemin. Methods for using anti-artemin antibodies and antigen-binding fragments are also provided.Type: GrantFiled: April 19, 2022Date of Patent: March 12, 2024Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Susan D. Croll, Lynn MacDonald, Andrew J. Murphy
-
Patent number: 11926675Abstract: Disclosed is an antibody that specifically binds CD24, or an antigen binding portion thereof. A nucleic acid molecule encoding the antibody or antigen binding portion thereof, an expression vector and a host cell comprising the nucleic acid molecule, a method for expressing the antibody or antigen binding portion thereof, and a method for treating a disease associated with CD24 signaling using the antibody or antigen binding portion thereof are also provided.Type: GrantFiled: March 3, 2022Date of Patent: March 12, 2024Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.Inventors: Wenzhi Tian, Song Li, Dianze Chen, Huiqin Guo
-
Patent number: 11926672Abstract: The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.Type: GrantFiled: December 18, 2020Date of Patent: March 12, 2024Assignee: Amgen Inc.Inventors: Xin Yu, Jackson Egen, Fernando Garces, Shunsuke Takenaka, AeRyon Kim, Deepali Sawant
-
Patent number: 11919947Abstract: A monoclonal antibody that binds ?-synuclein, and that binds tau fibrils, and methods of using the monoclonal antibody, are provided. The monoclonal antibody may be hybridoma clone 2F11. Also provided is a composition comprising the monoclonal antibody 2F11 and a pharmaceutically acceptable carrier, adjuvant, vehicle or excipient. A method of reducing active ?-synuclein in a subject in need thereof is also disclosed. The method involves administering an amount of the composition comprising 2F11 to the subject. The monoclonal antibody 2F11 may also be used to determine the ?-synuclein, or tau fibril, level in a biological sample.Type: GrantFiled: July 21, 2021Date of Patent: March 5, 2024Assignee: STRESSMARQ BIOSCIENCES INC.Inventor: Ariel Louwrier
-
Patent number: 11919951Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN6 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN6.Type: GrantFiled: February 7, 2022Date of Patent: March 5, 2024Assignees: Astellas Pharma Inc., TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität MainzInventors: Rita Mitnacht-Kraus, Stefan Wöll, Korden Walter, Özlem Türeci, Ugur Sahin
-
Patent number: 11912770Abstract: Provided are a single-domain antibody against human programmed death-ligand 1 (PD-L1) and application thereof. The PD-L1 binding molecule of the present invention can be used for treating and/or preventing, or diagnosing PD-L1 related diseases such as tumors.Type: GrantFiled: February 14, 2019Date of Patent: February 27, 2024Assignee: SHANGHAI NOVAMAB BIOPHARMACEUTICALS CO., LTD.Inventors: Yakun Wan, Min Zhu, Xiaoning Shen, Junwei Gai
-
Patent number: 11912777Abstract: The present invention relates to a novel antibody and antibody fragment that specifically binds to TNFR2 and to a composition comprising said antibody or antibody fragment. In addition, the present invention relates to a nucleic acid encoding the antibody or an antibody fragment thereof and a host cell comprising the same, and to a related use thereof. Besides, the present invention relates to the use of the antibody and antibody fragment for treatment and diagnosis.Type: GrantFiled: December 9, 2022Date of Patent: February 27, 2024Assignee: Nanjing Leads Biolabs Co., Ltd.Inventors: Xiaoqiang Kang, Shoupeng Lai, Xiao Huang, Huan Lin, Yujia Dang
-
Patent number: 11912759Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.Type: GrantFiled: May 4, 2021Date of Patent: February 27, 2024Assignees: NOVO NORDISK A/S, UNIVERSITY HEALTH NETWORKInventors: Yue Liu, Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
-
Patent number: 11912781Abstract: The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof a an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.Type: GrantFiled: January 13, 2022Date of Patent: February 27, 2024Assignee: Visterra, Inc.Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver, Lauren Olinski
-
Patent number: 11903985Abstract: The disclosure relates to compositions and methods for treatment of diseases associated with aberrant lysosomal function, such as Parkinson's disease and Gaucher disease. The disclosure provides expression constructs comprising a transgene encoding beta-glucocerebrosidase, an inhibitory RNA targeting alpha-Synuclein, or a combination of the foregoing. The disclosure further provides methods of treating Gaucher disease, Parkinson's disease or other synucleinopathies by administering such expression constructs to a subject in need thereof.Type: GrantFiled: April 10, 2020Date of Patent: February 20, 2024Assignee: Prevail Therapeutics, Inc.Inventors: Asa Abeliovich, Laura Heckman, Herve Rhinn, Franz Hefti
-
Patent number: 11906530Abstract: Methods are disclosed herein for determining whether a subject has a Tauopathy, such as Pick disease, Alzheimer disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) or argyrophilic grain disease (AGD). These methods utilize an amyloid seeding assay.Type: GrantFiled: December 29, 2017Date of Patent: February 20, 2024Assignee: The United States of America, as represented by the Secretary Department of Health and Human ServicesInventors: Byron Winslow Caughey, Eri Saijo, Allison Lindsey Kraus, Michael Anthony Metrick, II